The induced pluripotent stem cell (iPSC) market is segmented by derived cell type into hepatocytes, fibroblasts, keratinocytes, amniotic cells, and other derived cell types. The fibroblasts market was the largest segment of the induced pluripotent stem cell (iPSC) market segmented by derived cell type, accounting for 33.83% or $663.66 million of the total in 2024. Going forward, the hepatocytes segment is expected to be the fastest growing segment in the induced pluripotent stem cell (iPSC) market segmented by derived cell type, at a CAGR of 10.78% during 2024-2029.
The induced pluripotent stem cell (iPSC) market is segmented by application into academic research, drug discovery and toxicity studies, regenerative medicine, and cell and gene therapy. The drug discovery and toxicity studies market was the largest segment of the induced pluripotent stem cell (iPSC) market segmented by application, accounting for 41.04% or $805.14 million of the total in 2024. Going forward, the regenerative medicine segment is expected to be the fastest growing segment in the induced pluripotent stem cell (iPSC) market segmented by application, at a CAGR of 10.88% during 2024-2029.
The induced pluripotent stem cell (iPSC) market is segmented by end-user into academic and research institutes, pharmaceutical and biotechnology companies and other end users. The pharmaceutical and biotechnology companies market was the largest segment of the induced pluripotent stem cell (iPSC) market segmented by end-user, accounting for 53.43% or $1.04 billion of the total in 2024. Going forward, the academic and research institutes segment is expected to be the fastest growing segment in the induced pluripotent stem cell (iPSC) market segmented by end-user, at a CAGR of 11.49% during 2024-2029.
North America was the largest region in the induced pluripotent stem cell (iPSC) market, accounting for 41.77% or $819.41 million of the total in 2024. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the induced pluripotent stem cell (iPSC) market will be Asia Pacific and South America where growth will be at CAGRs of 11.60% and 9.39% respectively. These will be followed by North America and Eastern Europe where the markets are expected to grow at CAGRs of 9.15% and 8.79% respectively.
The global induced pluripotent stem cell (iPSC) market is fairly concentrated, with large number of small players operating in the market. The top ten competitors in the market made up to 30.52% of the total market in 2023. FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc) was the largest competitor with a 9.24% share of the market, followed by Thermo Fisher Scientific Inc. with 6.58%, STEMCELL Technologies Inc. with 3.63%, Lonza Group AG. with 3.06%, Miltenyi Biotec GmbH with 2.79%, Takara Bio Inc. with 1.55%, Astellas Pharma Inc. with 1.07%, Fate Therapeutics Inc. with 1.05, ViaCyte Inc. with 0.82% and Sartorius with 0.73%.
The top opportunities in the induced pluripotent stem cell (iPSC) market segmented by derived cell type will arise in the fibroblasts segment, which will gain $407.6 million of global annual sales by 2029. The top opportunities in the induced pluripotent stem cell (iPSC) market segmented by application will arise in the drug discovery and toxicity studies segment, which will gain $450.37 million of global annual sales by 2029. The top opportunities in the induced pluripotent stem cell (iPSC) market segmented by end-user will arise in the pharmaceutical and biotechnology companies segment, which will gain $543.74 million of global annual sales by 2029. The induced pluripotent stem cell (iPSC) market size will gain the most in the USA at $395.5 million.
Market-trend-based strategies for the induced pluripotent stem cell (iPSC) market include developing innovative ready-to-use, immune-cloaked iPSC cell lines, strategically investing by focusing on the development of advanced cell culture systems and tools to improve iPSC generation, focus on developing standardized, clinically compliant iPSC line, adopting strategic partnerships approach to develop advanced solutions and developing innovative, off-the-shelf kit models the human blood-brain barrier (BBB).
This report describes and explains the induced pluripotent stem cell (iPSC) market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global induced pluripotent stem cell (iPSC) market reached a value of nearly $1.96 billion in 2024, having grown at a compound annual growth rate (CAGR) of 10.74% since 2019. The market is expected to grow from $1.96 billion in 2024 to $3.09 billion in 2029 at a rate of 9.58%. The market is then expected to grow at a CAGR of 8.87% from 2029 and reach $4.73 billion in 2034.
Growth in the historic period resulted from increasing healthcare expenditure, increase in the prevalence of chronic disorders, growing interest in personalized medicine, increasing prevalence of neurological disorders and rising prevalence of genetic disorders. Factors that negatively affected growth in the historic period were high associated costs and tumorigenicity risks.
Going forward, rising number of clinical trials, growth in drug discovery and development, favorable government initiatives and growth in genomic projects will drive growth. Factor that could hinder the growth of the induced pluripotent stem cell (iPSC) market in the future include were limited reimbursement coverage and lack of awareness on induced pluripotent stem cell.
Player-adopted strategies in the induced pluripotent stem cell (iPSC) market include focus on expanding its business capabilities through new partnerships.
To take advantage of the opportunities, the analyst recommends the induced pluripotent stem cell (iPSC) market companies to focus on scaling allogeneic therapies with immune-cloaked iPSC lines, focus on advancing cell culture systems to improve iPSC efficiency and application, focus on standardized GMP-compliant iPSC lines to streamline development, focus on developing iPSC-derived BBB models to support CNS drug discovery, focus on hepatocytes to maximize growth opportunities, focus on regenerative medicine to drive long-term growth, expand in emerging markets, focus on strategic partnerships to accelerate iPSC development and commercialization, focus on competitive and value-based pricing to strengthen market position, focus on targeted outreach to key decision-makers in research and therapeutics, focus on strengthening digital channels to accelerate lead conversion and focus on academic and research institutes to capture highest growth.
This product will be delivered within 3-5 business days.
The induced pluripotent stem cell (iPSC) market is segmented by application into academic research, drug discovery and toxicity studies, regenerative medicine, and cell and gene therapy. The drug discovery and toxicity studies market was the largest segment of the induced pluripotent stem cell (iPSC) market segmented by application, accounting for 41.04% or $805.14 million of the total in 2024. Going forward, the regenerative medicine segment is expected to be the fastest growing segment in the induced pluripotent stem cell (iPSC) market segmented by application, at a CAGR of 10.88% during 2024-2029.
The induced pluripotent stem cell (iPSC) market is segmented by end-user into academic and research institutes, pharmaceutical and biotechnology companies and other end users. The pharmaceutical and biotechnology companies market was the largest segment of the induced pluripotent stem cell (iPSC) market segmented by end-user, accounting for 53.43% or $1.04 billion of the total in 2024. Going forward, the academic and research institutes segment is expected to be the fastest growing segment in the induced pluripotent stem cell (iPSC) market segmented by end-user, at a CAGR of 11.49% during 2024-2029.
North America was the largest region in the induced pluripotent stem cell (iPSC) market, accounting for 41.77% or $819.41 million of the total in 2024. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the induced pluripotent stem cell (iPSC) market will be Asia Pacific and South America where growth will be at CAGRs of 11.60% and 9.39% respectively. These will be followed by North America and Eastern Europe where the markets are expected to grow at CAGRs of 9.15% and 8.79% respectively.
The global induced pluripotent stem cell (iPSC) market is fairly concentrated, with large number of small players operating in the market. The top ten competitors in the market made up to 30.52% of the total market in 2023. FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc) was the largest competitor with a 9.24% share of the market, followed by Thermo Fisher Scientific Inc. with 6.58%, STEMCELL Technologies Inc. with 3.63%, Lonza Group AG. with 3.06%, Miltenyi Biotec GmbH with 2.79%, Takara Bio Inc. with 1.55%, Astellas Pharma Inc. with 1.07%, Fate Therapeutics Inc. with 1.05, ViaCyte Inc. with 0.82% and Sartorius with 0.73%.
The top opportunities in the induced pluripotent stem cell (iPSC) market segmented by derived cell type will arise in the fibroblasts segment, which will gain $407.6 million of global annual sales by 2029. The top opportunities in the induced pluripotent stem cell (iPSC) market segmented by application will arise in the drug discovery and toxicity studies segment, which will gain $450.37 million of global annual sales by 2029. The top opportunities in the induced pluripotent stem cell (iPSC) market segmented by end-user will arise in the pharmaceutical and biotechnology companies segment, which will gain $543.74 million of global annual sales by 2029. The induced pluripotent stem cell (iPSC) market size will gain the most in the USA at $395.5 million.
Market-trend-based strategies for the induced pluripotent stem cell (iPSC) market include developing innovative ready-to-use, immune-cloaked iPSC cell lines, strategically investing by focusing on the development of advanced cell culture systems and tools to improve iPSC generation, focus on developing standardized, clinically compliant iPSC line, adopting strategic partnerships approach to develop advanced solutions and developing innovative, off-the-shelf kit models the human blood-brain barrier (BBB).
This report describes and explains the induced pluripotent stem cell (iPSC) market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global induced pluripotent stem cell (iPSC) market reached a value of nearly $1.96 billion in 2024, having grown at a compound annual growth rate (CAGR) of 10.74% since 2019. The market is expected to grow from $1.96 billion in 2024 to $3.09 billion in 2029 at a rate of 9.58%. The market is then expected to grow at a CAGR of 8.87% from 2029 and reach $4.73 billion in 2034.
Growth in the historic period resulted from increasing healthcare expenditure, increase in the prevalence of chronic disorders, growing interest in personalized medicine, increasing prevalence of neurological disorders and rising prevalence of genetic disorders. Factors that negatively affected growth in the historic period were high associated costs and tumorigenicity risks.
Going forward, rising number of clinical trials, growth in drug discovery and development, favorable government initiatives and growth in genomic projects will drive growth. Factor that could hinder the growth of the induced pluripotent stem cell (iPSC) market in the future include were limited reimbursement coverage and lack of awareness on induced pluripotent stem cell.
Player-adopted strategies in the induced pluripotent stem cell (iPSC) market include focus on expanding its business capabilities through new partnerships.
To take advantage of the opportunities, the analyst recommends the induced pluripotent stem cell (iPSC) market companies to focus on scaling allogeneic therapies with immune-cloaked iPSC lines, focus on advancing cell culture systems to improve iPSC efficiency and application, focus on standardized GMP-compliant iPSC lines to streamline development, focus on developing iPSC-derived BBB models to support CNS drug discovery, focus on hepatocytes to maximize growth opportunities, focus on regenerative medicine to drive long-term growth, expand in emerging markets, focus on strategic partnerships to accelerate iPSC development and commercialization, focus on competitive and value-based pricing to strengthen market position, focus on targeted outreach to key decision-makers in research and therapeutics, focus on strengthening digital channels to accelerate lead conversion and focus on academic and research institutes to capture highest growth.
This product will be delivered within 3-5 business days.
Table of Contents
1 Executive Summary
6 Market Characteristics
7 Major Market Trends
8 Global Induced Pluripotent Stem Cell (iPSC) Growth Analysis And Strategic Analysis Framework
9 Global Induced Pluripotent Stem Cell (iPSC) Market Segmentation
10 Induced Pluripotent Stem Cell (iPSC) Market, Regional and Country Analysis
11 Asia-Pacific Market
12 Western Europe Market
13 Eastern Europe Market
14 North America Market
15 South America Market
16 Middle East Market
17 Africa Market
18 Competitive Landscape And Company Profiles
19 Other Major Companies
22 Key Mergers And Acquisitions
23 Recent Developments In The Induced Pluripotent Stem Cell (iPSC) Market
24 Opportunities And Strategies
25 Induced Pluripotent Stem Cell (iPSC) Market, Conclusions And Recommendations
26 Appendix
Executive Summary
Induced Pluripotent Stem Cell (iPSC) Global Market Opportunities And Strategies To 2034 provides the strategists; marketers and senior management with the critical information they need to assess the global induced pluripotent stem cells (iPSC) market as it emerges from the COVID-19 shut down.Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Description
Where is the largest and fastest-growing market for induced pluripotent stem cells (iPSC)? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The induced pluripotent stem cells (iPSC) market global report answers all these questions and many more.The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s history and forecasts market growth by geography. It places the market within the context of the wider induced pluripotent stem cells (iPSC) market; and compares it with other markets.
The report covers the following chapters
- Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by derived cell type, by application and by end-user.
- Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
- Growth Analysis And Strategic Analysis Framework- Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
- Global Market Size And Growth- Global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional And Country Analysis - Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
- Market Segmentation - Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by derived cell type, by application and by end-user in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
- Regional Market Size and Growth- Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Other Major And Innovative Companies- Details on the company profiles of other major and innovative companies in the market.
- Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
- Competitive Dashboard- Briefs on competitive dashboard of major players.
- Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market covered in the report.This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
- Recent Developments- Information on recent developments in the market covered in the report.
- Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Conclusions And Recommendations- This section includes recommendations for induced pluripotent stem cells (iPSC) providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
- Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered:
1) By Derived Cell Type: Hepatocytes; Fibroblasts; Keratinocytes; Amniotic Cells; Other Derived Cell Types2) By Application: Academic Research; Drug Discovery And Toxicity Studies; Regenerative Medicine; Cell And Gene Therapy
3) By End-User: Academic And Research Institutes; Pharmaceutical And Biotechnology Companies; Other End Users
Key Companies Profiled: FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc); Thermo Fisher Scientific Inc.; STEMCELL Technologies Inc.; Lonza Group AG; Miltenyi Biotec GmbH
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
Regions:Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; induced pluripotent stem cells (iPSC) indicators comparison.
Data Segmentation: Country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Companies Mentioned
- FUJIFILM Holdings Corporation (FUJIFILM Cellular Dynamics, Inc)
- Thermo Fisher Scientific Inc.
- STEMCELL Technologies Inc.
- Lonza Group AG
- Miltenyi Biotec GmbH
- Takara Bio Inc.
- Astellas Pharma Inc.
- Fate Therapeutics Inc.
- ViaCyte Inc.
- Sartorius
- Cynata Therapeutics Limited
- Shenzhen Bioscience
- Dainippon Sumitomo Pharma
- Shanghai Cell Therapy Group
- Car-T Bio
- JW Therapeutics
- Fosun Kite Biotechnology
- Shanghai UniCar Therapy
- Shinobi Therapeutics
- Merck Sharp & Dohme
- Evolus
- Merz Pharma
- AbbVie
- Ipsen
- AusBiotech Ltd
- LifeCell International
- iPS Bio, Inc.
- Karis Bio
- Cellino Biotech
- MEDIPOST Co., Ltd.
- Qilu Pharmaceutical Co., Ltd
- Japan Tissue Engineering Co., Ltd
- Nuwacell Biotechnologies Co., Ltd.
- Shanghai IxCell Biotech Co., Ltd.
- iRegene Therapeutics
- CellSeed, Inc.
- Celltrion
- Galderma SA
- HUGEL, Inc
- Croma-Pharma GmbH
- Fastox Pharma SA
- Avectas
- Albumedix Ltd
- Kite Pharma
- Gilead Sciences
- Renuron Group
- Smart Cells
- Genenta Science
- CellGenix
- Cellcolabs AB
- Axol Bioscience
- RigeneranD S.r.l.
- SEED Biosciences SA
- Selvita
- Mabion S.A.
- Roche Holding AG
- Resolution Therapeutics
- Ncardia BV
- Evotec A.G.
- Alzheon
- Zentiva Group, a.s.
- Bochemie a.s.
- Tolion Health
- Sinclair Pharma
- Pfizer
- Pharmasyntez
- Mabion
- Pure Biologics
- Proteon Pharmaceuticals
- GlaxoSmithKline
- Parexel
- Bayer
- Synbio Technologies
- OmniaBio
- Medipost Co
- QHP Capital
- Applied StemCell
- Century Therapeutics
- Bristol Myers Squibb
- StemCyte, Inc.
- Vertex Pharmaceuticals Incorporated
- Fate Therapeutics
- ThermoGenesis Holdings
- BioCanRx
- CellCAN
- CCRM
- C3i
- Gameto
- BioCells
- Banco de Cordon del Peru
- CryoHoldco
- Rege Nephro
- CellSave Arabia
- Life Cell
- AmiCare
- Cells4life
- ReeLabs
- Royan Stem Cell Technology Co.
- Next BioSciences
- CryoSave
- BioHeart
- Net Cells
- Cell Safe Bank
- StemPlus
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 346 |
Published | September 2025 |
Forecast Period | 2024 - 2034 |
Estimated Market Value ( USD | $ 1.96 Billion |
Forecasted Market Value ( USD | $ 4.73 Billion |
Compound Annual Growth Rate | 9.2% |
Regions Covered | Global |
No. of Companies Mentioned | 104 |